CompletedEarly Phase 1

RAS and Coagulopathy in COVID19

United Kingdom28 participantsStarted 2020-10-09

Plain-language summary

To determine whether the coagulopathy associated with COVID-19 infection is driven by overactivation of the renin angiotensin system (RAS)

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Hospitalised with confirmed COVID-19 infection.
✓. Screened within 96hrs of SARS-COV-2 positive PCR.
✓. Age 18 or over
✓. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
✓. Systolic blood pressure between 100 and 180

✕. Any unrelated clinical condition, which, in the opinion of the investigator, may affect D-dimer during the course of the study, independent of COVID-19 infection, e.g. subsets of cancers and coagulopathies.
✕. Concomitant medication which inhibit the action of TRV027 (ARB's).
✕. Any clinically significant medical conditions that in the opinion of the investigator would compromise subjects' safety or compliance with study procedures.
✕. Any clinical condition which in the opinion of the principal investigator would compromise the scientific integrity of the study
✕. Unwillingness or inability to follow the procedures outlined in the protocol.
✕. Subject is pregnant or breastfeeding

Coagulopathy Associated With COVID-19

Timeframe: Day 1 (baseline) and Day 3).

NCT IDNCT04419610

SponsorImperial College London

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-05-12

Results submitted2022-09-27